Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/012097ANTI-HUMAN MSLN ANTIBODY AND MSLN-TARGETING IMMUNE EFFECTOR CELL
WO 20.01.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2021/086067 Applicant HRAIN BIOTECHNOLOGY CO., LTD. Inventor HUANG, Fei
The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.
2.WO/2022/012682CD22 BINDING MOLECULES AND USES THEREOF
WO 20.01.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/106891 Applicant NANJING LEGEND BIOTECH CO., LTD. Inventor FAN, Xiaohu
The present disclosure provides single domain antibodies that bind to CD22, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
3.WO/2022/013762METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER
WO 20.01.2022
Int.Class G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
Appl.No PCT/IB2021/056326 Applicant PINTO, Aldo Inventor PINTO, Aldo
The present invention relates to a method for the diagnosis and/or to monitor the development and/or to provide a prognosis on the development of lung cancer in an individual, including the detection of the expression levels of the isoform 4 of the human caspase-4 protein in biological samples. The present invention further relates to a kit and reagents for the detection of the expression levels of said isoform 4, as well as a compound inhibitor of said isoform 4 for use in the treatment and/or prevention of lung cancer.
4.WO/2022/015082THERAPEUTIC USE OF GLUCAGON DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASE
WO 20.01.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/KR2021/009124 Applicant HANMI PHARM. CO., LTD. Inventor KIM, Jung Kuk
The present invention relates to a therapeutic use of a glucagon derivative or a conjugate thereof for liver disease.
5.WO/2022/015922HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
WO 20.01.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2021/041737 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor LEVIN, Noam
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
6.WO/2022/011436METHODS OF TREATING CORONAVIRUS INFECTION WITH BOVINE-HYPERIMMUNE COLOSTRUM
WO 20.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/AU2021/050772 Applicant IMMURON LIMITED Inventor KANELLOS, Jerry
A method of treating and/or preventing human coronavirus infection in a subject comprising administering an effective amount of a composition comprising bovine-hyperimmune colostrum prepared using a vaccine comprising enterotoxigenic E. coli (ETEC) LPS.
7.WO/2022/011466DUAL FUNCTION SURFACE FOR CELL CAPTURE AND SPREADING
WO 20.01.2022
Int.Class C07K 17/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
17Carrier-bound or immobilised peptides; Preparation thereof
Appl.No PCT/CA2021/050968 Applicant THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY Inventor A. HOESLI, Corinne
There is provided a surface functionalized with cross linking groups adapted to receive antibodies and/or fragments thereof. The surface has an antibody binding biomolecule having a linker region which is covalently crosslinked to functional groups and an antibody binding region. The surface also has a cell interacting biomolecule having a linker region which is covalently crosslinked to functional groups of the surface and a cell interacting region that imparts functional attributes including cell adhesion, spreading, proliferation, differentiation and/or a functional response. The two biomolecules are present in independently controlled concentrations and have similar small molecular weights.
8.WO/2022/012606ANTIBODIES BINDING C5 AND USES THEREOF
WO 20.01.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2021/106391 Applicant BIOSION INC. Inventor CHEN, Mingjiu
An isolated monoclonal antibody that specifically binds human C5, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided are a bispecific molecule, an immunoconjugate, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an anti-C5 antibody or the antigen-binding portion thereof.
9.WO/2022/012636GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL17A AND/OR IL17F
WO 20.01.2022
Int.Class C12N 15/90
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
90Stable introduction of foreign DNA into chromosome
Appl.No PCT/CN2021/106559 Applicant BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Inventor SHEN, Yuelei
Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL17A and/or IL17F, and methods of use thereof.
10.WO/2022/012681MULTISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
WO 20.01.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2021/106889 Applicant NANJING LEGEND BIOTECH CO., LTD. Inventor FAN, Xiaohu
The present disclosure provides chimeric antigen receptors targeting CD20, CD19 and/or CD22. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.